Amarin Corp Plcuk (AMRN) Change in Acquisitions & Divestments (2020 - 2026)
Amarin Corp Plcuk (AMRN) reported Change in Acquisitions & Divestments of $42.5 million for Q1 2026, down 22.73% year-over-year from $55.0 million in Q1 2025, and down 9.58% quarter-over-quarter from $47.0 million in Q4 2025.
Amarin Corp Plcuk (AMRN) Change in Acquisitions & Divestments (2020 - 2026) Analysis & Trends
Amarin Corp Plcuk (AMRN) has 7 years of Change in Acquisitions & Divestments data on file, last reported at $42.5 million in Q1 2026.
- Change in Acquisitions & Divestments for Q1 2026 came in at $42.5 million, down 22.73% year-over-year; the trailing twelve-month figure through Mar 2026 was $196.8 million (down 12.84% YoY), and the FY2025 annual result was $209.3 million, down 10.09% from the prior year.
- Change in Acquisitions & Divestments retreated to $42.5 million in Q1 2026 per AMRN's latest filing, from $47.0 million in the prior quarter.
- Over five years, Change in Acquisitions & Divestments peaked at $113.2 million in Q1 2022 and troughed at $16.9 million in Q4 2022.
- A 5-year average of $54.8 million and a median of $54.2 million in 2022 frame the typical range for Change in Acquisitions & Divestments.
- The sharpest annual moves came in 2022 and 2024: Change in Acquisitions & Divestments slumped 79.42% in 2022, then soared 88.38% in 2024.
- A 5-year view of Change in Acquisitions & Divestments shows it stood at $16.9 million in 2022, then soared by 72.19% to $29.1 million in 2023, then jumped by 61.45% to $47.0 million in 2024, then gained by 0.0% to $47.0 million in 2025, then slipped by 9.58% to $42.5 million in 2026.
- Business Quant data shows AMRN's Change in Acquisitions & Divestments at $42.5 million in Q1 2026, $47.0 million in Q4 2025, and $57.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Amarin Corp Plcuk | 5.84 Bn | 5.66 Bn | 17.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 42.50 Mn |
| Mar 31, 2026 | 42.50 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Dec 31, 2025 | 47.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Sep 30, 2025 | 57.00 Mn |
| Jun 30, 2025 | 50.30 Mn |
| Jun 30, 2025 | 50.30 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Mar 31, 2025 | 55.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Dec 31, 2024 | 47.00 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Sep 30, 2024 | 52.80 Mn |
| Jun 30, 2024 | 71.00 Mn |
| Jun 30, 2024 | 71.00 Mn |
| Mar 31, 2024 | 62.00 Mn |
| Mar 31, 2024 | 62.00 Mn |
| Dec 31, 2023 | 29.11 Mn |
| Dec 31, 2023 | 29.11 Mn |